UroGen Pharma Ltd. Forecast, price target & analysts
UroGen Pharma Ltd. Target price 2026 - Analyst rating & recommendation
UroGen Pharma Ltd. Classifications & Recommendation
UroGen Pharma Ltd. Price Target
| Target Price | $60.18 |
| Price | $43.95 |
| Potential |
36.93%
register free of charge
|
| Number of Estimates | 10 |
|
10 Analysts have issued a price target UroGen Pharma Ltd. 2027 .
The average UroGen Pharma Ltd. target price is $60.18.
This is
36.93%
register free of charge
$78.75
79.18%
register free of charge
$48.48
10.31%
register free of charge
|
|
| A rating was issued by 14 analysts: 12 Analysts recommend UroGen Pharma Ltd. to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the UroGen Pharma Ltd. stock has an average upside potential 2027 of
36.93%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 109.79 | 328.65 |
| 21.45% | 199.34% | |
| EBITDA Margin | -113.45% | 5.66% |
| 6.34% | 104.99% | |
| Net Margin | -139.80% | -5.28% |
| 0.38% | 96.22% |
10 Analysts have issued a sales forecast UroGen Pharma Ltd. 2026 . The average UroGen Pharma Ltd. sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an UroGen Pharma Ltd. EBITDA forecast 2026. The average UroGen Pharma Ltd. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
10 UroGen Pharma Ltd. Analysts have issued a net profit forecast 2026. The average UroGen Pharma Ltd. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -3.19 | -0.36 |
| 7.77% | 88.71% | |
| P/E | negative | |
| EV/Sales | 6.73 |
10 Analysts have issued a UroGen Pharma Ltd. forecast for earnings per share. The average UroGen Pharma Ltd. EPS is
This results in the following potential growth metrics and future valuations:
UroGen Pharma Ltd....
Current UroGen Pharma Ltd. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Aug 06 2026 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Aug 06 2026 |
| TD Cowen |
Locked
➜
Locked
|
Locked | Aug 05 2026 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Jul 21 2026 |
| Oppenheimer |
Locked
➜
Locked
|
Locked | Jul 16 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jun 03 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | May 18 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Aug 06 2026 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Aug 06 2026 |
|
Locked
TD Cowen:
Locked
➜
Locked
|
Aug 05 2026 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Jul 21 2026 |
|
Locked
Oppenheimer:
Locked
➜
Locked
|
Jul 16 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jun 03 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
May 18 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
